Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-57569
Beyer, C; Distler, O; Distler, J H W (2012). Biomarkers of fibrosis. In: Varga, J; Denton, C P; Wigley, F M. Scleroderma: From Pathogenesis to Comprehensive Management. Boston, 283-290. ISBN 978-1-4419-5773-3.
PDF - Registered users only
Biomarkers are modern diagnostics that can guide the treatment of our patients in daily clinical life and direct drug development in preclinical and clinical studies. Biological markers allow screening for diseases, giving prognostic information, and assessing disease activity. Over the last 20 years, biomarkers helped to prioritize drug development and minimize risks for drug attrition in late-phase clinical studies. Despite their central roles in modern medicine, the numbers of disease-specific biomarkers that we routinely assess in our patients with systemic sclerosis (SSc) are limited. So far, past medical history, clinical examination, and equipment-based diagnostics (e.g., computed tomography, body plethysmography, and right-heart catheterization studies) dominate our treatment decisions in SSc.
|Item Type:||Book Section, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine|
|DDC:||610 Medicine & health|
|Deposited On:||09 Mar 2012 14:38|
|Last Modified:||21 Sep 2012 05:15|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page